Hiconcil Combi (Amoxicillin, Clavulanic Acid)

Hiconcil Combi is indicated for the treatment of a range of bacterial infections that are susceptible to amoxicillin‑clavulanic acid. Common clinical situations include respiratory, urinary, and skin infections where β‑lactamase‑producing bacteria are suspected.

• Acute bacterial sinusitis, especially when caused by Streptococcus pneumoniae or Haemophilus influenzae.
• Acute otitis media in children and adults, including cases with mixed flora.
• Community‑acquired pneumonia caused by typical and atypical pathogens.
• Uncomplicated urinary tract infections due to Escherichia coli or other susceptible organisms.
• Skin and soft‑tissue infections such as cellulitis, impetigo, or infected wounds.
• Infections where β‑lactamase‑producing strains are known or suspected.

• Amoxicillin, a broad‑spectrum β‑lactam penicillin, covalently attaches to penicillin‑binding proteins (PBPs) that catalyze the final stages of peptidoglycan synthesis, thereby halting cross‑linking of the bacterial cell wall and causing osmotic rupture. Clavulanic acid, although possessing only weak intrinsic antibacterial activity, acts as a suicide inhibitor of β‑lactamase enzymes by forming a stable acyl‑enzyme complex, which shields amoxicillin from enzymatic hydrolysis. This dual action broadens coverage to β‑lactamase‑producing strains.

Adverse reactions to Hiconcil Combi are generally mild, but serious events can occur; patients should be aware of both common and rare but severe effects.

Common

• Nausea, vomiting or abdominal discomfort.
• Diarrhea, which may be watery or loose.
• Skin rash or mild urticaria.
• Headache or dizziness.
• Mild taste alteration.
• Mild photosensitivity.

Serious

• Severe allergic reactions such as anaphylaxis, angioedema, or Stevens‑Johnson syndrome.
• Clostridioides difficile‑associated colitis presenting with profuse watery diarrhea.
• Hepatotoxicity indicated by jaundice, elevated liver enzymes, or hepatitis.
• Hematologic abnormalities such as neutropenia, thrombocytopenia, or hemolytic anemia.
• Seizures in patients with renal impairment.
• Acute interstitial nephritis.

Before prescribing Hiconcil Combi, clinicians should evaluate patient history and clinical factors to minimize risk of adverse outcomes.

• Assess for known hypersensitivity to penicillins, β‑lactamase inhibitors, or any component of the formulation.
• Use caution in patients with a history of liver disease, as clavulanic acid may increase hepatic enzyme levels.
• Adjust dosage or avoid use in severe renal impairment because drug clearance is reduced.
• Monitor for signs of Clostridioides difficile infection during and after therapy.
• Avoid use in pregnant or breastfeeding women unless the benefit outweighs potential risk, due to limited safety data.
• Consider alternative agents in patients with a history of severe allergic reactions to β‑lactams.

Hiconcil Combi can interact with other medicines, altering efficacy or increasing toxicity; relevant interactions are grouped below.

Avoid

• Concurrent use with all oral anticoagulants such as warfarin, which may increase bleeding risk.
• Combination with allopurinol, which has been associated with severe skin reactions when given with amoxicillin‑clavulanate.
• Use with probenecid, which reduces renal excretion of amoxicillin and may raise plasma concentrations.
• Simultaneous use with macrolide antibiotics (e.g., erythromycin) that may increase the risk of hepatotoxicity.

Use with caution

• Concomitant administration of methotrexate, as reduced renal clearance may enhance toxicity.
• Co‑administration with oral contraceptives, which may experience decreased effectiveness.
• Use with other nephrotoxic agents (e.g., aminoglycosides) in patients with impaired renal function.
• Caution when combined with antacids containing aluminum or magnesium, which can reduce amoxicillin absorption.
• Monitor liver function when given with other hepatotoxic drugs.